Enhancement of Protein Breakdown through PKG-mediated Phosphorylation of the Proteasome
Enhancement of Protein Breakdown through PKG-mediated Phosphorylation of the Proteasome
批准号:
9792258
负责人:
Jordan VerPlank
金额:
$6.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2020-08-31
关键词:
26S proteasomeAdenylate CyclaseAffectAftercareAgingAlzheimer&aposs DiseaseAmyotrophic Lateral SclerosisAutophagocytosisBiochemicalBrainCatalytic DomainCell AggregationCellsCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic GMPCyclic GMP-Dependent Protein KinasesDiseaseDisease ProgressionExhibitsFDA approvedFailureFrontotemporal DementiaGoalsHeartHumanImpairmentInvestigationLysosomesMammalian CellMass Spectrum AnalysisMediatingMethodsModelingModificationMusNeurodegenerative DisordersParkinson DiseasePeptide HydrolasesPharmacologyPhosphodiesterase InhibitorsPhosphorylationPhosphotransferasesPhysiologic pulsePhysiologicalProteinsSite-Directed MutagenesisSoluble Guanylate CyclaseSystemTauopathiesTestingTherapeuticTissuesUbiquitinUbiquitinationZebrafishbasecell typecombatfrontotemporal lobar dementia-amyotrophic lateral sclerosisgenetic regulatory proteininhibitor/antagonistmisfolded proteinmulticatalytic endopeptidase complexmutantneuroblastoma cellnovel strategiesoverexpressionphosphodiesterase IVpreventprotein Bprotein degradationproteostasisproteotoxicitysildenafilsuperoxide dismutase 1tau mutation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract
The ubiquitin proteasome system (UPS) degrades the majority of proteins in mammalian cells and one
of its primary functions is to selectively eliminate misfolded, potentially toxic proteins. In the UPS, protein
substrates are modified by the attachment of chains of ubiquitin molecules, which target the protein for rapid
degradation by the 26S proteasome. It is generally assumed that ubiquitination determines the rate of protein
degradation by the UPS, but recent studies have shown that the activity of 26S proteasomes is tightly
regulated and can determine rates of protein degradation in cells. Our lab and collaborators recently found that
agents that raise cAMP cause the Protein Kinase A-mediated phosphorylation of the 26S subunit Rpn6 and the
enhancement of multiple proteasome activities. This modification increases the capacity in cells and mouse
brains to degrade misfolded, aggregation-prone proteins (e.g. mutant Tau and SOD1) that cause
neurodegenerative diseases. Thus, pharmacological enhancement of proteasome function is an exciting new
approach to combat various aging-associated diseases.
I recently found that treatments that raise cGMP and activate Protein Kinase G also stimulate
proteasome activity and protein degradation in cells. This cGMP-mediated stimulation was not due to Rpn6
phosphorylation, and therefore occurs by a different mechanism than raising cAMP. I am proposing an in-depth
investigation to determine 1.) how raising cGMP stimulates proteasome function, 2.) the effect of raising cGMP
on the degradation of different types of cell proteins and 3.) whether FDA-approved pharmacological agents
that increase cGMP levels (e.g. PDE5 inhibitors) enhance the clearance of mutant proteins that cause
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and Parkinson’s Disease.
These studies should clarify the mechanisms and importance of this new mode of regulating protein
degradation and its therapeutic potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金